X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.fiercebiotech.com/biotech/merck-gileads-weekly-hiv-combo-maintains-viral-suppression-its-early-days-primary-endpoint
https://www.ema.europa.eu/en/documents/overview/sunlenca-epar-medicine-overview_en.pdf
https://www.fiercepharma.com/pharma/gileads-lenacapivir-approved-first-class-long-acting-hiv-injectable
https://www.prnewswire.com/news-releases/fda-approves-new-hiv-drug-for-adults-with-limited-treatment-options-301709176.html
https://www.pharmacompass.com/pdf/news/gileads-sunlenca-lenacapavir-receives-approval-in-europe-58869.pdf
https://www.fiercepharma.com/pharma/gileads-first-class-long-acting-hiv-med-snags-eu-nod-after-fda-track-derailed-manufacturing
https://endpts.com/four-months-after-crl-due-to-contaminant-worries-gilead-returns-to-fda-for-next-gen-hiv-drug/
https://www.biopharmadive.com/news/gilead-clinical-hold-lift-fda-lenacapavir-hiv/623902/
https://www.marketwatch.com/story/gilead-sciences-says-fda-lifts-clinical-hold-on-injectable-lenacapavir-271652733093
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-gileads-hiv-treatment-glass-vial-concerns-2022-03-01/
https://www.fiercepharma.com/manufacturing/particulate-problem-prompts-hold-10-gilead-studies-hiv-hopeful-lenacapavir
http://www.pharmafile.com/news/600775/fda-places-clinical-hold-use-injectable-lenacapavir-hiv-treatment
https://www.clinicaltrialsarena.com/news/fda-gilead-hiv-therapy-trials-hold/
https://www.fiercebiotech.com/biotech/merck-pauses-2-more-trials-backbone-hiv-drug-over-red-flag-raising-doubts-about-multi
https://endpts.com/mercks-experimental-hiv-drug-islatravir-hits-with-a-phiii-combo-win-and-fda-filing-plans/
https://www.clinicaltrialsarena.com/analysis/lenacapavir-gilead-outlook/
https://www.clinicaltrialsarena.com/analysis/lenacapavir-gilead-outlook/
https://www.clinicaltrialsarena.com/news/gilead-lenacapavir-virologic-suppression/
https://www.businesswire.com/news/home/20210309005909/en/Gilead%E2%80%99s-Investigational-Lenacapavir-Demonstrates-Sustained-Long-Acting-Efficacy-Through-Week-26-in-Data-Presented-at-CROI/?feedref=JjAwJuNHiystnCoBq_hl-WFAllVCLJFCqzlmaJ8DKHU4plfPZtlGYRDUHCSmgbii6XkLWuQZD-HgGRnjQvCyg3iCfEFIaJW7-otp9V1XQiK2eHTJy3ZqOEt7kKgLu20J
http://www.pharmafile.com/news/564149/gileads-lenacapavir-meets-primary-goal-heavily-treated-and-multidrug-resistant-hiv-1
https://www.gilead.com/news-and-press/press-room/press-releases/2020/11/gilead-announces-investigational-longacting-hiv1-capsid-inhibitor-lenacapavir-achieves-primary-endpoint-in-phase-23-study-in-heavily-treatmentex
Market Place
Share 
